Common causes include metabolic syndrome, insulin resistance, non-alcoholic fatty liver disease, chronic inflammation from obesity, haemochromatosis, viral hepatitis, excessive alcohol consumption, or malignancy
Frontiers in Molecular Biosciences, 7 , 552056
, ,
The past two years have seen unprecedented momentum: GLP-1 therapies moved from niche to mainstream, supply issues arose then abated, and asset pipelines expanded beyond weight loss to whole-body medications
Compounded medications often use chemical salt forms such as semaglutide sodium or acetate, which are not identical to the FDA-approved molecules
This regulatory expansion has effectively doubled the addressable market by incorporating weight management patients alongside diabetic populations